XORTX Announces Change of Auditor
XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focusing on progressive kidney disease and gout treatments, has announced a change in its auditor. The company's board has accepted the resignation of Smythe LLP and appointed Davidson & Company LLP as the new auditor effective January 16, 2025.
The transition occurred without any reservations in the Former Auditor's reports or any reportable events. The required documentation, including the Notice of Change of Auditor and letters from both auditing firms, has been reviewed by the company's audit committee and board of directors, and filed on SEDAR+.
XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX | Francoforte: ANU), una compagnia farmaceutica in fase avanzata di sviluppo che si concentra sul trattamento delle malattie renali progressive e della gotta, ha annunciato un cambiamento nel suo revisore. Il consiglio di amministrazione della società ha accettato le dimissioni di Smythe LLP e ha nominato Davidson & Company LLP come nuovo revisore a partire dal 16 gennaio 2025.
La transizione è avvenuta senza alcuna riserva nei rapporti del Revisore Precedente o eventi segnalabili. La documentazione richiesta, incluso l'Avviso di Cambio di Revisore e le lettere di entrambe le società di revisione, è stata esaminata dal comitato di audit e dal consiglio di amministrazione della società, ed è stata depositata su SEDAR+.
XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), una compañía farmacéutica en etapa clínica avanzada enfocada en tratamientos para enfermedades progresivas del riñón y gota, ha anunciado un cambio en su auditor. La junta de la compañía ha aceptado la renuncia de Smythe LLP y ha nombrado a Davidson & Company LLP como el nuevo auditor, efectivo el 16 de enero de 2025.
La transición se llevó a cabo sin reservas en los informes del Auditor Anterior ni en eventos que deban ser reportados. La documentación requerida, incluyendo el Aviso de Cambio de Auditor y cartas de ambas firmas de auditoría, ha sido revisada por el comité de auditoría y la junta directiva de la compañía, y se ha presentado en SEDAR+.
XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX | 프랑크푸르트: ANU), 진행성 신장병 및 통풍 치료에 주력하는 후기 단계 임상 제약 회사가 감사인 변경을 발표했습니다. 회사 이사회는 Smythe LLP의 사임을 수락하고 2025년 1월 16일부터 Davidson & Company LLP를 새로운 감사인으로 임명했습니다.
이 전환은 이전 감사인의 보고서에서 어떤 유보 사항이나 보고할 사건 없이 이루어졌습니다. 필요한 문서, 즉 감사인 변경 통지 및 두 감사 firm's의 서신이 회사 감사 위원회와 이사회에서 검토되었으며, SEDAR+에 제출되었습니다.
XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX | Francfort : ANU), une entreprise pharmaceutique en fin de développement clinique axée sur les traitements des maladies rénales progressives et de la goutte, a annoncé un changement de commissaire aux comptes. Le conseil d'administration de la société a accepté la démission de Smythe LLP et a nommé Davidson & Company LLP comme nouveau commissaire aux comptes, à compter du 16 janvier 2025.
La transition s'est déroulée sans aucune réserve dans les rapports de l'ancien commissaire aux comptes ni dans les événements à signaler. La documentation requise, y compris l'Avis de Changement de Commissaire aux Comptes et les lettres des deux cabinets d'audit, a été examinée par le comité d'audit et le conseil d'administration de l'entreprise, et a été déposée sur SEDAR+.
XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), ein pharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Behandlung von fortschreitenden Nierenerkrankungen und Gicht spezialisiert hat, hat eine Änderung seines Wirtschaftsprüfers bekannt gegeben. Der Vorstand des Unternehmens hat das Rücktrittsgesuch von Smythe LLP akzeptiert und Davidson & Company LLP zum neuen Wirtschaftsprüfer ernannt, wirksam ab dem 16. Januar 2025.
Der Wechsel erfolgte ohne Vorbehalte in den Berichten des vorherigen Wirtschaftsprüfers oder meldenswerten Ereignissen. Die erforderliche Dokumentation, einschließlich der Mitteilung über den Wechsel des Wirtschaftsprüfers und den Schreiben beider Wirtschaftsprüfungsgesellschaften, wurde vom Prüfungsausschuss und dem Vorstand des Unternehmens überprüft und bei SEDAR+ eingereicht.
- None.
- None.
CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the Company has changed its auditor from Smythe LLP, Chartered Professional Accountants (“Former Auditor”) to Davidson & Company LLP, Chartered Professional Accountants, (“Successor Auditor”) effective January 16, 2025.
XORTX’s board of directors accepted the resignation of the Former Auditor, as of January 16, 2025 and appointed the Successor Auditor as the new auditor of the Company effective January 16, 2025, and to hold office until the close of the Company's next annual general meeting of shareholders.
There were no reservations in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor. There are no "reportable events" (as the term is defined in National Instrument 51-102 - Continuous Disclosure Obligations) between the Company and the Former Auditor.
In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Company's audit committee and board of directors and have been filed on the Company’s SEDAR+ profile at www.sedarplus.ca.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; 2) our XRx-026 program for the treatment of allopurinol intolerant gout; and 3) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and health of kidney disease patients and individuals with gout. Additional information on XORTX is available at www.xortx.com.
| For more information, please contact: | |
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com or +1 403 455 7727 | nick@alpineequityadv.com or +1 617 901 0785 |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
FAQ
When did XORTX Therapeutics (XRTX) change its auditor?
Were there any reservations or reportable events in XRTX's auditor change?
Who is XORTX's new auditor as of January 2025?
How long will XRTX's new auditor Davidson & Company LLP serve?
